Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02720510
Title A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

multiple myeloma

Therapies

Panobinostat

Bortezomib + Dexamethasone + Lenalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.